
    
      MASTER is prospective, randomized (3:1), single blind, controlled, superiority (efficacy) and
      non-inferiority (safety and efficacy), multi center, two-arm trial of TCD-10023 (Ultimaster)
      drug eluting stent (test) and Kaname bare metal stent (comparator).

      Patients will be followed at 30 days, 6, and 12 months post-procedure and annually for 3
      years.

      500 patients with clinical follow up will be randomized in 3:1 ratio (375 in TCD-10023 arm
      and 125 in Kaname arm). Among them, 100 patients will be randomized in the same, 3:1 ratio,
      to angiographic follow up at 6 months in preselected hospitals (75 in TCD-10023 and 25 in
      Kaname arm)
    
  